Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial.

Authors: Writing Group for the PEPI Trial.

Publication Year:1995

Citation: JAMA 1995; 273(3):199-208.

Bioidentical progesterone (an oral micronized preparation) was used in one group in the PEPI study in place of medroxyprogesterone acetate (MPA).  Results showed that the progesterone group had significantly higher HDL cholesterol levels than the MPA group, indicating a different pharmacological effect than the synthetic progestin with a more favorable effect on blood lipids.

http://www.ncbi.nlm.nih.gov/pubmed/7807658